Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zura Bio Limited - Class A Ordinary shares (NQ:ZURA)

5.505 +0.075 (+1.38%)
Streaming Delayed Price Updated: 3:46 PM EDT, Aug 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 322,939
Open 5.460
Bid (Size) 5.500 (300)
Ask (Size) 5.510 (1,000)
Prev. Close 5.430
Today's Range 5.261 - 5.545
52wk Range 1.390 - 7.440
Shares Outstanding 62,064,270
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Analyst Sees Multi-Billion-Dollar Sales Potential for Zura Bio’s Lead Therapy ↗
William Blair starts Zura Bio (NASDAQ: ZURA) at Outperform, citing tibulizumab's multibillion-dollar potential in autoimmune disease. 
Via Benzinga
News headline image
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
From Zura Bio Limited
Via Business Wire

Performance

YTD
-0.8%
-0.8%
1 Month
+2.7%
+2.7%
3 Month
+3.5%
+3.5%
6 Month
-4.6%
-4.6%
1 Year
+277.1%
+277.1%

More News

Read More
News headline image
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer
From Zura Bio Limited
Via Business Wire
ZURA BIO LTD (NASDAQ:ZURA) Q1 2026: Cash Runway Extended Through 2028 as Phase 2 Trials Advance ↗
Via Chartmill
News headline image
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio to Participate in Upcoming Investor Conferences
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Zura Bio Limited
Via Business Wire
News headline image
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Reports Business Updates and Outlook for 2026
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates
From Zura Bio Limited
Via Business Wire
News headline image
Unusual volume stocks are being observed in Wednesday's session. ↗
Via Chartmill
News headline image
Here are the top movers in Tuesday's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga
News headline image
These stocks are moving in today's session ↗
Via Chartmill

Frequently Asked Questions

Is Zura Bio Limited - Class A Ordinary shares publicly traded?
Yes, Zura Bio Limited - Class A Ordinary shares is publicly traded.
What exchange does Zura Bio Limited - Class A Ordinary shares trade on?
Zura Bio Limited - Class A Ordinary shares trades on the Nasdaq Stock Market
What is the ticker symbol for Zura Bio Limited - Class A Ordinary shares?
The ticker symbol for Zura Bio Limited - Class A Ordinary shares is ZURA on the Nasdaq Stock Market
What is the current price of Zura Bio Limited - Class A Ordinary shares?
The current price of Zura Bio Limited - Class A Ordinary shares is 5.505
When was Zura Bio Limited - Class A Ordinary shares last traded?
The last trade of Zura Bio Limited - Class A Ordinary shares was at 08/03/26 03:46 PM ET
What is the market capitalization of Zura Bio Limited - Class A Ordinary shares?
The market capitalization of Zura Bio Limited - Class A Ordinary shares is 341.66M
How many shares of Zura Bio Limited - Class A Ordinary shares are outstanding?
Zura Bio Limited - Class A Ordinary shares has 342M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Penticton Herald, Penticton, BC. Powered by BLOX Content Management System from TownNews.com.